China & Manufacturing Patent Grants

We’ve achieved some exciting IP milestones for Calla Lily Clinical Care; making strong progress in building a robust IP strategy and IP portfolio to protect and advance our innovations in women’s health.

💥 China Patent Grant for our Drug Delivery Device 🌏
At long last, one of our vaginal drug delivery applications in China has been granted (ZL202080032097.8) — a significant milestone in our global IP strategy. With declining birthrates in China, Japan, Korea and Singapore 📉 , the need for technologies that support IVF and miscarriage prevention has never been more urgent. We now have granted patents in *all* of these key markets, further solidifying our presence in Asia.

💥 UK Patent Grant for our Manufacturing Innovation 🌍
During the last year we have also secured a UK patent (GB2590903) covering our proprietary joining technology— a critical innovation in how our device integrates multiple component materials. I still recall the in-depth discussions with our technical team and IP advisors debating which novel aspects of our manufacturing should be patented and which to keep as trade secrets — an illustration that strategic IP decisions are never straightforward!

Developing a strong, defensible, and valuable IP portfolio is a complex, resource-intensive process. Congratulations to our team and external IP advisors— led by our CFO and head of IP, Stuart Prince—for driving these efforts forward! 💪

We use cookies to enhance your website experience. We use necessary cookies to ensure our website functions properly and to keep it secure. These always need to be on. By clicking “Accept cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyse site usage, and assist in our marketing efforts. Please view our privacy policy for further details.